The oncology space continued its trend of developing innovative therapies — both those launching and in the pipeline — in 2018. That's according to a new report from the IQVIA Institute for Human Data Science titled Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications. And while the outlook continues to look promising in terms of the science, it may pose issues to the health care system that need to be resolved in order to take full advantage of next-generation oncology products, AIS Health reported.
The 15 new oncology drugs and one supportive care drug launched last year for 17 tumor types marked a record. "Importantly, one of the new drugs is tissue-agnostic" — Loxo Oncology, Inc. and Bayer Corp.'s Vitrakvi (larotrectinib) — noted Murray Aitken, executive director of the institute, during a May 23 media call to discuss the report’s findings. "Over half of the new drugs are oral therapies, continuing this trend toward more of the targeted, innovative therapies being available in an oral form. Two-thirds of the new drugs have an orphan indication, continuing this trend towards cancer being redefined into narrower segments."
Among the new drugs, more than half have a predictive biomarker on their label.
"This is a trend, the movement towards precision medicine and the growing role that predictive biomarkers are having, both in the way in which the drugs are tested in the clinic, as well as used in practice, where patients can be tested for a biomarker in advance of being treated with a particular drug," maintained Aitken.
This level of innovation, however, has meant a surge in spending for these treatments.
Total spending on all oncology drugs, both therapeutics and supportive care products, globally was almost $150 billion, up 12.9% for the year, which "marks the fifth consecutive year of double-digit growth," said Aitken.
In the U.S., "spending on cancer drugs has doubled since 2013 and exceeded $56 billion in 2018," he noted.